Table 2 Characteristics of all studies included.
Studies | Counties | Populations | Participants | Sex | Age (years) | Interventions | Designs | Outcomes |
|---|---|---|---|---|---|---|---|---|
Costigan et al.32 | Australia | Adolescents | I: n = 22 C: n = 22 | 11 M/11F 11 M/11F | 15.5 ± 0.6 15.6 ± 0.6 | 8 weeks 3 times/week | Parallel | ③ |
Connolly et al.33 | UK | Women | I: n = 15 C: n = 15 | 0 M/15F 0 M/15F | 44 ± 7 45 ± 7 | 12 weeks 3 times/week | Parallel | ④ |
Mezcua-Hidalgo et al.34 | Spain | Adolescents | I: n = 77 C: n = 81 | 42 M/35F 38 M/43F | 13.88 ± 1.25 14.20 ± 1.31 | Acute | Parallel | ① |
Coetsee and Terblanche35 | South Africa | Older adults | I: n = 13 C: n = 19 | 3 M/10F 8 M/11F | 64.5 ± 6.3 62.5 ± 5.6 | 16 weeks 3 times/week | Parallel | ②③ |
Chua et al.23 | Singapore | Children | I: n = 38 C: n = 25 | 0 M/38F 0 M/25F | NA NA | Acute | Parallel | ④ |
Brown and Bray36 | Canada | University students | I: n = 22 C: n = 20 | NA NA | 19.95 ± 1.96 20.85 ± 1.66 | Acute | Parallel | ③ |
Northey et al.21 | Australia | Female cancer survivors | I: n = 6 C: n = 6 | 0 M/6F 0 M/6F | 60.3 ± 8.1 61.5 ± 7.8 | 12 weeks 3 times/week | Parallel | ③④ |
Lee et al.37 | Canada | Adolescents hospitalized for a mental illness | n = 28 | 8 M/20F | 15.5 ± 0.92 | Acute | Cross-over | ②③ |
Mekari et al.38 | Canada | Adults | I: n = 12 C: n = 13 | 3 M/9F 4 M/9F | 29 ± 10.3 35 ± 7.4 | 6 weeks 3 times/week | Parallel | ②③ |
Hatch et al.39 | UK | Adolescents | n = 38 | 15 M/23F | 12.4 ± 0.4 | Acute | Cross-over | ②③④ |
Zimmer et al.40 | Switzerland | Multiple sclerosis | I: n = 27 C: n = 30 | 7 M/20F 12 M/18F | 51 ± 9.9 48 ± 12.1 | 3 weeks 3 times/week | Parallel | ①②③④ |
Oliveira et al.41 | Brazil | Overweight/obese adults | I: n = 11 C: n = 10 | NA NA | 29.7 ± 8.3 33.2 ± 6.6 | 12 weeks 3 times/week | Parallel | ③ |
Kendall et al. 42 | USA | Young adults | I: n = 20 C: n = 19 | 8 M/12F 9 M/10F | 22.7 ± 3.3 22.8 ± 1.4 | Acute | Parallel | ⑤ |
De Lima et al.43 | Brazil | Middle-aged overweight men | I: n = 13 C: n = 12 | 13 M/0F 12 M/0F | 39.46 ± 5.44 40.50 ± 5.63 | 8 weeks 3 times/week | Parallel | ②③④ |
Wang et al.44 | China | College students | I: n = 26 C: n = 28 | 17 M/9F 15 M/13F | 21.98 ± 2.25 22.79 ± 2.36 | 6 weeks 3 times/week | Parallel | ③④ |
Liu et al.22 | China | Young adults | I: n = 26 C: n = 20 | 11 M/15F 10 M/10F | 24.83 ± 2.35 25.42 ± 2.61 | 12 weeks 3 times/week | Parallel | ③ |
Kao et al.45 | USA | Children | I: n = 25 C: n = 24 | 13 M/12F 14 M/10F | 9.2 ± 0.8 8.7 ± 0.8 | Acute | Parallel | ③ |
Zhu et al.46 | China | Healthy young males | n = 16 | 16 M/0F | 21 ± 1.7 | Acute | Cross-over | ③ |
Gjellesvik et al.47 | Norway | Adult stroke survivors | I: n = 36 C: n = 34 | 21 M/15F 20 M/14F | 57.6 ± 9.2 58.7 ± 9.2 | 8 weeks 3 times/week | Parallel | ② |
Rivas-Campo et al.48 | Colombia | Older adults | I: n = 64 C: n = 68 | 26 M/38F 27 M/41F | 77.11 ± 7.3 77.19 ± 7.7 | 12 weeks 3 times/week | Parallel | ①②③ |
